M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177 Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

The centre will leverage fully automated lesion segmentation in PSMA-PET/CT imaging. Malaysia’s Sunway Medical Centre, Sunway ...

Subscribe for FREE This advanced imaging technology plays a critical role in redefining how prostate cancer is staged. PSMA-PET imaging uses tiny amounts of radioactive “tracers,” called radiotracers, ...

New consensus recommendations address implementation of novel treatments and imaging techniques for advanced and ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center, published in JAMA Network Open, shows that nearly half of the ...

A new UCLA Health Jonsson Comprehensive Cancer Center-led study has revealed that advanced prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging could reveal ...

Prostate cancer stands as the third most common cancer among Malaysian men, with 70 percent of cases diagnosed at advanced ...

Telix’s lead imaging product, gallium-68 ( 68 Ga) gozetotide injection (also known as 68 Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug ...